Bayer Animal Health
and Bioiberica Companion Animal Health
have signed a strategic distribution agreement to distribute and market selected products from Bioiberica's portfolio in Germany, Austria, France, Belgium, the Netherlands and Korea starting in the first quarter of 2020. For Spain and Portugal, the two companies have concluded a co-marketing agreement to jointly market the products.
The selected product portfolio includes innovative nutritional solutions and dermatological products whose effectiveness has been scientifically proven. This helps to preserve the health of dogs and cats suffering from chronic diseases in the fields of joint health (Condrovet® Force HA), dermatology (Atopivet® Spot-On and Atopivet® Capsules), and internal medicine (Impromune®, Calmurofel® and EnteroChronic®). The products, made with high quality ingredients and developed and manufactured by Bioiberica, support the physiological response of the animals to the above mentioned diseases.
"We at Bayer Animal Health are committed to promoting the health and well-being of animals. This partnership enables us to expand our portfolio into new and attractive areas for the benefit of animals. This will also strengthen our role as a solution provider for our business partners," commented Nikolaus Hiester, Head of Business Operations, Commercial Operations Europe at Bayer Animal Health.
"This partnership is critical to Bioiberica's international expansion plans. We combine our specialization in the development, production and marketing of high-quality ingredients and our knowledge of science, regulations and market understanding with Bayer's leadership and experience to offer new products that improve the health and quality of life of companion and farm animals," said Alfonso Velasco, Bioiberica Companion Animal Health Director.